Mirikizumab-mrkz

(Omvoh)

Mirikizumab-mrkz

Drug updated on 12/19/2023

Dosage FormInjection (intravenous: 300 mg/15 mL (20 mg/mL) in a single-dose vial; subcutaneous: 100 mg/mL in a single-dose prefilled vial)
Drug ClassInterleukin-23 antagonist
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of moderately to severely active ulcerative colitis in adults

Product Monograph / Prescribing Information

Document TitleYearSource
OMVOH (mirikizumab-mrkz) prescribing information2023Eli Lilly

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
1,162Subjects
F: 40%
M: 60%
2023The New England journal of medicine.
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
249Subjects
F: 40%
M: 60%
2023Clinical and translational gastroenterology
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
249Subjects
F: 40%
M: 60%
2023BMJ open gastroenterology
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
530Subjects
F: 30%
M: 70%
2022The British journal of dermatology.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
191Subjects
F: 51%
M: 49%
2022Gastroenterology
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
234Subjects
F: 41%
M: 59%
2022Clinical gastroenterology and hepatology
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology.
249Subjects
F: 40%
M: 60%
2020Gastroenterology
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
205Subjects
F: 26%
M: 74%
2019The British journal of dermatology.

Sex Distribution:

F:40%
M:60%
1162Subjects

Year:

2023

Source:The New England journal of medicine.


Sex Distribution:

F:40%
M:60%
249Subjects

Year:

2023

Source:Clinical and translational gastroenterology


Sex Distribution:

F:30%
M:70%
530Subjects

Year:

2022

Source:The British journal of dermatology.


Sex Distribution:

F:51%
M:49%
191Subjects

Year:

2022

Source:Gastroenterology


Sex Distribution:

F:41%
M:59%
234Subjects

Year:

2022

Source:Clinical gastroenterology and hepatology


Sex Distribution:

F:40%
M:60%
249Subjects

Year:

2020

Source:Gastroenterology


Sex Distribution:

F:26%
M:74%
205Subjects

Year:

2019

Source:The British journal of dermatology.

Clinical Practice Guidelines

Document TitleYearSource
A Practical Guide to the Use of Mirikizumab2023The American journal of gastroenterology